The ongoing coronavirus disease 2019 (COVID-19) pandemic has affected millions worldwide and has been found to cause severe disease in patients with underlying comorbidities. In patients with known malignancies, in addition to constraints in routine healthcare, the risk of being susceptible to developing severe forms of the disease is of grave concern. While follow-up studies on survivors of the severe acute respiratory syndrome (SARS) 2003 outbreak revealed increased susceptibility to infections, tumours and cardiovascular abnormalities, recent studies implicating angiopoietin 2 in induction of inflammatory intussusceptive angiogenesis and diffuse alveolar damage in COVID-19 patients raises the possibility of progression of carcinogenetic processes in patients with known malignancies. Angiotensin converting enzyme-2 (ACE-2) mediated cellular entry of SARS-Cov2 leads to receptor shedding of ACE-2 and disrupts the renin angiotensin aldosterone axis (RAAS). This augments the pro-inflammatory and proliferative effects of RAAS, while attenuating the anti-inflammatory and anti-proliferative angiotensin 1-7 /Mas pathway. Angiopoietin-2, a molecule responsible for angiogenesis and cancer progression which corelates with tumour load in certain cancers, is upregulated by angiotensin 2-AT1 Receptor axis. Tumour microenvironment-comprising of various cells, blood vessels and extra cellular matrix which express the RAAS peptides-plays a key role in cancer initiation, progression and metastasis. Angiotensin 2 induces the formation of a desmoplastic environment, favouring cancer cell growth. ACE-2 downregulation causes bradykinin accumulation which may exert its proliferative action via mitogen activated protein kinase pathways which has established roles in cancers of breast and kidney. In addition to cytokine storm causing organ damage, acute inflammation in COVID-19 may also cause epithelial mesenchymal transition and heat shock protein 27 phosphorylation, both of which are key mediators in cancer signalling pathways. We hypothesise that SARS-Cov2, by impacting the RAAS and immune system, has the potential to cause tumour cell proliferation, apoptosis evasion and metastasis, thereby increasing the possibility of cancer progression in patients with known malignancies.
Chilaiditi’s sign is a rare radiological diagnosis characterized by colonic interposition between the diaphragm and the liver, and when symptomatic it is known as Chilaiditi’s syndrome. We report that the case of a 55-years-old male, who was referred to our institution as a case of colitis, with the symptoms of recurrent vomiting, pain abdomen, and altered bowel habit, was eventually diagnosed to have Chilaiditi’s syndrome with non-specific colitis, after carefully taking the history and clinically examining the patient.
Background: Ingestion of wild mushrooms leading to toxicity is a common phenomenon every year during the rainy season in Upper Assam, India. The model for end-stage liver disease (MELD) score was developed to predict mortality in a specific group of patients with decompensated chronic liver disease. It has also been used to predict mortality in patients with acute liver failure, which is also one of the dreaded complications of mushroom toxicity. There are only a couple of studies in the world that have studied MELD score as a predictor of outcomes in patients with mushroom toxicity and to the best of our knowledge, this is the first such study done in India. Methods: In this hospital-based observational study, 35 patients aged >13 years with an alleged history of ingestion of wild mushrooms, but no other cause of hepatic dysfunction were included in this study. Disease outcome (discharged/expired) was correlated with both MELD score and day of presentation from symptom onset. Results: The mean age was 32.54 years with a male-to-female sex ratio of 4:5 among the study participants. Gastrointestinal symptoms, including loose stool, vomiting, pain abdomen, and jaundice, were the most common. The MELD score was significantly higher in patients who succumbed to the toxin (p<0.05) and positively correlated with mortality (r=0.664, p<0.001) and a later day of presentation (r=0.226, p=0.123). A later-day presentation also positively correlated with mortality (r=0.227, p=0.189). Conclusions: The MELD score can be used as a prognostic tool in patients with mushroom toxicity.
Background: Diabetes and thyroid dysfunctions are closely related to endocrine disorders. Research has shown that there is a clear connection between hyperinsulinemia, insulin resistance, increased glycated haemoglobin (HbA1c) levels, and abnormal thyroid function. Hypothyroidism is relatively common in diabetic patients, particularly in those with suboptimal glycemic control. As a result, screening for thyroid dysfunction in diabetic patients can aid in the early identification and treatment of hypothyroidism, potentially reducing the risk of complications associated with the condition. Objectives: Correlation of TSH and HbA1c in diabetic patients. Materials and Methods: This hospital-based cross-sectional study was conducted in the Department of Medicine, Assam Medical College, Dibrugarh, between February 2022 and February 2023. A total of 120 patients with diabetes attending the department without any prior history of thyroid disease or any factor that may affect thyroid function were included in this study. Thyroid-stimulating hormone (TSH) and HbA1c were done in all subjects. Results: The result showed that the mean age was 57.68 years with female preponderance (58.33%) and increased mean levels of HbA1c (7.8850%) and TSH (13.566 micro IU/mL). In our study, the mean serum TSH level was significantly higher in uncontrolled diabetes than that in controlled diabetes patients. HbA1c also showed a positive correlation (r = 0.574; P < 0.001) with thyroid abnormality. Conclusions: Conducting thyroid function screenings on diabetic patients can aid in the identification of asymptomatic hypothyroid patients. Early detection of underlying thyroid dysfunction facilitates timely treatment, which may enhance glycemic control and ultimately improve the quality of life for diabetic patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.